Top Story

JDRF launches diabetes psychology fellowship program

November 19, 2017

JDRF announced the launch of a National Diabetes Psychology Fellowship Program to address the shortage of psychologists who can treat the specific needs of people with type 1 diabetes.

The program aims to fund eight psychology fellows over the next 2 years to complete training in the field of diabetes at top centers in the US, according to a press release.

AMPK activator reduces glucose level in type 2 diabetes in phase 2a trial

November 18, 2017
A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial…
In the Journals

Nearly 1 in 7 patients with diabetes have poor glycemic control

November 17, 2017
About one in seven patients with diabetes had poor glycemic control between 2007 and 2014 despite an increase in the frequency of self-reported testing and patient…
In the Journals Plus

Patients with Addison's disease show no increase in adipose tissue

November 17, 2017
Although patients with Addison’s disease who were treated with glucocorticoids demonstrated increased cortisol exposure, they did not have increased levels of
In the Journals PlusPerspective

Heart failure strongest predictor of poor survival in type 2 diabetes

November 17, 2017
Older adults with type 2 diabetes are at increased risk for death from cardiovascular complications, with the strongest associations found between survival and heart…
More Headlines »

Ace the Case: A 39-Year-Old Man with Progressive Weight Gain

No commercial support for this activity.

This “Ace the Case” activity will use a case study to discuss obesity management in a patient with progressive weight…
More »
Meeting News

VIDEO: Patients not seeking, providers not offering enough obesity care

November 2, 2017
More »
Resource Centers



Understanding and Managing a Complex Dual Dilemma: Diabetes and Dyslipidemia

This activity is supported by an educational grant from Amgen.

Patients with type 2 diabetes have increased cardiovascular risk. Inhibitors of proprotein convertase subtilisin/kexin…
More »
Current Issues
View the Current Issue